Novo (NYSE: NVO) has tapped the Swedish drug-delivery developer Nanexa to develop long-acting injectable platforms for its peptide meds, with a global licensing deal worth €1.165 billion, or about $1.32 billion U.S. The deal will support up to five R&D programs targeting monthly and quarterly injections, as the drugmaker looks to extend the reach of […]
injection device
7 recommendations to increase training consistency for patients self-injecting biologics
Biologic drugs are finding growing success in addressing chronic diseases — from diabetes and rheumatoid arthritis to multiple sclerosis and Crohn’s. A significant rise in self-injection therapies is contributing to the trend. And yet, a recent study1 of injection naïve patients found that only 50% reported receiving a visual representation of the self-injection from a […]
